Pyrimidine derivatives of formula (I) wherein Q.sub.1, Q.sub.2, G and
R.sup.1 are as defined within; and pharmaceutically acceptable salts and
in vivo hydrolysable esters thereof are described. Processes for their
manufacture, pharmaceutical compositions and their use as cyclin-dependent
serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors
are also described.
##STR1##
